Skip to main content
Avicanna Inc. logo

Avicanna Inc. — Investor Relations & Filings

Ticker · AVCN ISIN · CA05368K1003 LEI · 254900AUQ4URGWO3FN90 TSX Manufacturing
Open in API
Filings indexed 484 across all filing types
Latest filing 2020-08-17 Interim / Quarterly Rep…
Country CA Canada
Listing TSX AVCN

About Avicanna Inc.

https://www.avicanna.com/

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based, cannabinoid-based products for the global medical and pharmaceutical markets. The company operates through four commercial pillars: Medical Cannabis Products (RHO Phyto™), a Medical Cannabis Care Platform (MyMedi.ca), a Pharmaceutical Pipeline, and Active Pharmaceutical Ingredients (Aureus Santa Marta™). Avicanna leverages an industry-leading scientific platform, including R&D collaborations with academic institutions and a robust IP portfolio, resulting in over 50 proprietary commercialized SKUs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'AVICANNA REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE' and contains detailed financial data for the three and six months ended June 30, 2020, including revenues, expenses, net loss, balance sheet items, and operational highlights. It includes comprehensive financial statements and analysis for a quarterly period, which is characteristic of an Interim / Quarterly Report. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement or summary. There is no indication that this is merely an announcement of a report or a certification letter. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q2 2020
2020-08-17 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification by the CFO regarding the interim financial statements and interim MD&A for the period ended June 30, 2020. It is a Form 52-109F2 certification of interim filings, which is an officer attestation about the accuracy and fairness of the interim financial reports. The document does not contain the actual interim financial statements or substantive financial data, but rather certifies their review and compliance. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the interim report itself (IR). The document length is 3238 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2020-08-15 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F2 Certification of Interim Filings by the CEO of Avicanna Inc. It certifies the review and fair presentation of interim financial statements and interim MD&A for the period ended June 30, 2020. The document is primarily an officer certification letter confirming the accuracy and completeness of the interim filings and the design of internal controls. It does not contain the actual interim financial statements or substantive financial data itself, but rather attests to their validity. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) itself. The document length is 3367 characters, which is relatively short and consistent with a certification letter rather than a full interim report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-08-15 English
Interim MD&A - English.pdf
Regulatory Filings
2020-08-15 English
Interim financial statements/report – English.pdf
Regulatory Filings
2020-08-15 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the nationwide availability of Avicanna's RHO Phyto medical cannabis product line in Canada through Medical Cannabis by Shoppers Inc. It details product features, manufacturing standards, partnerships, and commercialization strategy. There is no presentation of financial data, regulatory filings, voting results, or management changes. The document is a corporate announcement about product commercialization and market availability, not a financial report, regulatory filing, or meeting material. Therefore, it fits best under the category of a general regulatory announcement or corporate news release that does not fit other specific categories.
2020-08-12 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.